A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial
Journal article published in 2016 by
Jan C. Drooger,
Harm van Tinteren 
,
Steffen M. de Groot,
Albert J. ten Tije,
Hiltje de Graaf,
Johanneke E. A. Portielje ,
Agnes Jager,
Aafke Honkoop,
Sabine C. Linn,
Judith R. Kroep,
Frans L. G. Erdkamp,
Paul Hamberg,
Alex L. T. Imholz,
Quirine C. van Rossum-Schornagel,
Joan B. Heijns
and other authors.
,
Steffen M. de Groot,
Albert J. ten Tije,
Hiltje de Graaf,
Johanneke E. A. Portielje ,
Agnes Jager,
Aafke Honkoop,
Sabine C. Linn,
Judith R. Kroep,
Frans L. G. Erdkamp,
Paul Hamberg,
Alex L. T. Imholz,
Quirine C. van Rossum-Schornagel,
Joan B. Heijns
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 